Efficient Delivery of the CRISPR-Cas System to Primary Cells by Peptide-Assisted Genome Editing

Immuno-Oncology Webinar Presented by Dr. Zhen Zhang

Join us for a live webinar with Dr. Zhen Zhang on January 23, 2024. In this talk, Dr. Zhang from the Perelman School of Medicine, University of Pennsylvania, will discuss his latest findings on the development and application of an engineered peptide-assisted genome editing (PAGE) CRISPR-Cas system for efficient editing of primary cells. The presentation will be followed by a live Q&A session. Register now and submit your questions in advance for the speaker to answer during the Q&A session.

Efficient Delivery of the CRISPR-Cas System to Primary Cells by Peptide-Assisted Genome Editing

Date: Tuesday, January 23, 2024
Time: 9 - 10 a.m. PST | 12 p.m. EST | 5 p.m. UTC*

*If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.

Speaker:
Zhen Zhang, PhD
Research Associate at the Perelman School of Medicine, University of Pennsylvania

Description:
Simple, fast, and efficient delivery of CRISPR-Cas systems to primary cells remains a challenge in basic and clinical studies. In this webinar, Dr. Zhang will discuss his recent work published in Nature Biotechnology, which describes an engineered peptide-assisted genome editing (PAGE) CRISPR-Cas system for efficient editing of primary cells with minimal toxicity, providing a broadly generalizable platform for next-generation genome editing in primary cells.

Topics:

Development of CRISPR-Cas PAGE system
Development of CRISPR-RNP-PAGE genome editing in human CAR T cells
PAGE-mediated multiplex genome editing in human CAR T cells and hematopoietic stem and progenitor cells (HSPCs)

Dr. Zhen Zhang graduated from Dr. Chad Slawson's laboratory at the University of Kansas Medical Center in 2017. He then joined Drs. Shelley Berger and Junwei Shi's laboratory at the University of Pennsylvania as a postdoctoral researcher. His research interests include, but are not limited to, cancer epigenetics, immunotherapy and the study of epigenetic and transcriptional regulation of T cell exhaustion, and development of CRISPR-Cas delivery tools for primary cells, especially primary T cells.